abstracts: https://doi.org/10.1182/blood-2018-120779
This data as json
| doi | article_title | article_date | session_type | topics | author_names | author_affiliations | first_author_latitude | first_author_longitude |
|---|---|---|---|---|---|---|---|---|
| https://doi.org/10.1182/blood-2018-120779 | A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912) | November 29, 2018 | Late-Breaking Abstracts Session | ["cancer research", "chronic b-cell leukemias", "chronic lymphocytic leukemia", "cyclophosphamide", "eastern cooperative oncology group", "electrocorticogram", "fludarabine", "ibrutinib", "phase 3 clinical trials", "rituximab"] | ["Tait D. Shanafelt, MD", "Victoria Wang", "Neil E. Kay, MD", "Curtis A. Hanson, MD", "Susan M. O'Brien, MD", "Jacqueline C Barrientos, MD", "Harry P. Erba, MDPhD", "Richard M. Stone, MD", "Mark R. Litzow, MD", "Martin S. Tallman, MD"] |